Consistent with the findings in vitro, administration of AE-AS greatly reduced the protein expression of HIF-1α, VEGF, and pVEGFR2, as well as tumor angiogenesis reflected by a decrease of CD31 expression. The gene discussed is HIF1A; the disease is neoplasm.